B
Bullisch
Bullisch · 25%CLGN
$10.06
Szenariopreis
$3.970
+0.030 (+0.76%)Zum Schluss
Loading chart…
- Hoch
- 4.189
- Eröffnung
- 4.180
- Volumengewichteter Durchschnittskurs
- 4.00
- Volumen
- 29.22K
- Marktkap.
- 57.27M
- Tief
- 3.850
- Umsatz
- 116.96K
- EV/EBITDA, TTM
- -0.06
CollPlant Biotechnologies Ltd, formerly known as Collplant Holdings Ltd, is a company dealing in aesthetic medicine and regenerative medicine based in Israel. The company provides products and technologies for broadly understood regenerative medicine, including tissue regeneration and organ production. The technology is based on plants and is based on the production of collagen type I (rhCollagen).
KI-Analyse of Collplant Biotechnologies Ltd (CLGN)
HaltenCollPlant Biotechnologies Ltd is not a strong buy right now due to its current price of $3.97, which is significantly below its 52-week high of $22.50, indicating a potential for recovery but also high risk. The company has a forward P/E ratio of 80, suggesting that it is highly valued relative to its earnings, which are currently negative. Additionally, the RSI is at 47.809, indicating a neutral momentum, and the stock has experienced a year-to-date change of -73.18%, reflecting ongoing challenges. The main risk is its high volatility, with an implied volatility of 671.43%, which could lead to significant price swings.
Bewertungskennzahlen
Das aktuelle erwartete KGV von Collplant Biotechnologies Ltd (CLGN) beträgt 80.00, verglichen mit dem 5-Jahres-Durchschnitt von 16.78.
Alphio-AI-Kursszenarien für CLGN
Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.
Event-Zeitleiste
News
8.510-09PRnewswireCollPlant Secures Private Placement to Accelerate R&D
3.510-06PRnewswireCollPlant Advances Photonic Computing Strategy
3.510-06NewsfilterCollPlant Advances Photonic Computing Strategy Through LightSolver's IP Growth
8.509-30PRnewswireCollPlant Expands into Photonic Computing with LightSolver Acquisition
- 8.509-30Newsfilter
CollPlant Acquires LightSolver to Expand Technology Portfolio
CLGN FAQ – beantwortet von Alphio AI
CollPlant Biotechnologies Ltd, formerly known as Collplant Holdings Ltd, is a company dealing in aesthetic medicine and regenerative medicine based in Israel. The company provides products and technologies for broadly understood regenerative medicine, including tissue regeneration and organ production. The technology is based on plants and is based on the production of collagen type I (rhCollagen). It operates in the Healthcare sector (ORTHOPEDIC, PROSTHETIC, AND SURGICAL APPLIANCES AN industry).
CollPlant Biotechnologies Ltd is not a strong buy right now due to its current price of $3.97, which is significantly below its 52-week high of $22.50, indicating a potential for recovery but also high risk. The company has a forward P/E ratio of 80, suggesting that it is highly valued relative to its earnings, which are currently negative. Additionally, the RSI is at 47.809, indicating a neutral momentum, and the stock has experienced a year-to-date change of -73.18%, reflecting ongoing challenges. The main risk is its high volatility, with an implied volatility of 671.43%, which could lead to significant price swings.
Community
Mehr ↗Noch keine Beiträge
Registriere dich oder melde dich an, um mitzudiskutierenÄhnliche Artikel
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.